Novartis’ Exforge To Launch By End Of June
This article was originally published in The Pink Sheet Daily
Executive Summary
Launch timeframe for the combination of firm’s Diovan and Pfizer’s Norvasc is a few months earlier than previously expected due to recent invalidation of Norvasc patent.
You may also be interested in...
Novartis’ Diovan Gets Pediatric Hypertension Nod
Novartis’ top seller will compete with Merck’s Cozaar in the growing pediatric high blood pressure market.
Novartis’ Diovan Gets Pediatric Hypertension Nod
Novartis’ top seller will compete with Merck’s Cozaar in the growing pediatric high blood pressure market.
Daiichi Sankyo/Forest’s Hypertension Therapy Azor Gets FDA Nod
Azor will compete against Novartis’ recently approved Exforge.